article thumbnail

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

European Journal of Heart Failure

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.

article thumbnail

GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF

American College of Cardiology

What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?

article thumbnail

University Hospitals Researcher Develops New Score System to Better Screen and Treat HFpEF Heart Failure Patients

DAIC

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

article thumbnail

Adiposity, fat-free mass and incident heart failure in 500 000 individuals

Open Heart

Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95% CI 1.32 to 1.45) than general adiposity (BMI adjusted for WC; HR 1.22, 95% CI 1.16 Results Over a median follow-up of 13.8 years, there were 10 455 first-ever incident HF events. to 2.07).

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%

article thumbnail

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Circulation

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.

article thumbnail

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Circulation

The H2FPEF score and probability were developed to assist in heart failure with preserved ejection fraction (HFpEF) diagnosis. Results:Overall, 140 participants were identified (age: 56±16 years; BMI: 30.04±8.04 kg/m2; 74% female) with normal left ejection fraction (LVEF: 63±9%). 2022 were included.